MOVE
Movano Inc.
MOVE's outlook is improving, though it still trails on the overall score.
OSCR
Oscar Health, Inc.
OSCR has the edge over MOVE overall, supported by stronger fundamentals.
MOVE Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Under pressure | |
| Weak | |
| Unavailable |
MOVE's revenue is currently strong, but its profitability and cash flow are under pressure. There isn't enough data to rate its balance sheet.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
MOVE PE Valuation
MOVE has no meaningful PE right now: it lost money over the past year.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR's PE is 13x, but its earnings don't support one, so it isn't a reliable read right now.
MOVE Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| -- | |
| Limited | |
| High |
Analysts expect MOVE's losses to shrink, with revenue growing.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for OSCR, with profitability improving.
MOVE Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$18.64 | +$10.13 |
| Q1 2026 | -$17.62 | +$16.05 |
| Q4 2025 | -$21.79 | +$19.58 |
| Q3 2025 | -$22.90 | +$25.20 |
| Q2 2025 | -$28.77 | +$35.73 |
| Q1 2025 | -$33.67 | +$47.33 |
| Q4 2024 | -$41.37 | +$53.13 |
| Q3 2024 | -$48.10 | +$67.40 |
MOVE is still losing money, but far less than before: $18.64 per share over the past year, against $227.31 at its worst in late 2021.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has the edge over MOVE on earnings quality, reporting a profit while its opponent remains loss making.
MOVE Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5M | +6128% |
| Q2 2026 | $3.8M | +3590% |
| Q1 2026 | $510K | +148% |
| Q4 2025 | $44K | -60% |
| Q3 2025 | $80K | +60% |
| Q2 2025 | $103K | +348% |
| Q1 2025 | $206K | -76% |
MOVE's revenue is growing: $5M last quarter, up 6128% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -350% | +2889 points |
| Q2 2026 | -400% | +2765 points |
| Q1 2026 | -950% | +1592 points |
| Q4 2025 | -10032% | -5805 points |
| Q3 2025 | -3239% | +11519 points |
| Q2 2025 | -3165% | +24648 points |
| Q1 2025 | -2543% | -1867 points |
| Q4 2024 | -4227% | N/A |
MOVE's operating margin was −350% last quarter, up 2889 points from the same quarter a year ago, near the top of its range since 2024.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over MOVE on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR has the edge over MOVE on profitability, with a higher operating margin.
MOVE Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q4 2025 | -$2.3M | +$2.3M |
| Q4 2024 | -$4.6M | +$702K |
| Q3 2024 | -$5.7M | +$1.3M |
| Q2 2024 | -$8.2M | -$262K |
| Q1 2024 | -$4.1M | +$2M |
| Q4 2023 | -$5.3M | +$1.1M |
| Q3 2023 | -$7M | -$517K |
| Q2 2023 | -$7.9M | -$1.5M |
OSCR has the stronger cash trend. Its trailing FCF is up 545% versus its history, compared with MOVE at down 70%.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR usually generates cash, though not every quarter: the latest was −$1.2B, but it generated $4.1B over the past year.
MOVE Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +54% | +878K shares |
| 1 year | +252% | +1.8M shares |
| 3 years | +1041% | +2.3M shares |
| 5 years | +17% | +365K shares |
MOVE has 3M diluted shares, up 252% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
| Q4 2019 | — |
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has the edge over MOVE on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
MOVE Net Leverage
MOVE's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has more cash than debt.
MOVE Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.2 | Neutral |
| Stochastic | 1.9 | Oversold |
MOVE's weekly RSI is 36 (neutral) and its Stochastic is 2 (oversold).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
MOVE PE vs Healthcare Sector
MOVE has no meaningful PE right now: it lost money over the past year.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
MOVE Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $8.27 | 43% below |
| 20 week MA | $11.0 | 57% below |
| 50 week MA | $12.7 | 63% below |
| 100 week MA | $16.0 | 70% below |
| 200 week MA | $66.2 | 93% below |
MOVE is in a downtrend: it's below all five of its weekly moving averages, and 93% below its 200-week average.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over MOVE on trend strength, trading above more of its moving averages.
MOVE Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $846.0 | $447.0 | -47% |
| 2022 | $447.0 | $219.0 | -51% |
| 2023 | $219.0 | $117.2 | -46% |
| 2024 | $117.2 | $58.5 | -50% |
| 2025 | $58.5 | $8.14 | -86% |
| 2026 YTD | $8.14 | $4.71 | -42% |
MOVE has finished every year since 2021 lower, and it's down 42% so far in 2026.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over MOVE on returns for 2026, with the stronger performance.